Detalhe da pesquisa
1.
The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML.
Blood
; 136(5): 596-609, 2020 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-32270193
2.
Incidence and socioeconomic factors in older adults with acute myeloid leukaemia: Real-world outcomes from a population-based cohort.
Eur J Haematol
; 108(5): 437-445, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35122325
3.
Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Br J Haematol
; 181(6): 782-790, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29741758
4.
The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells.
Blood
; 123(23): 3622-34, 2014 Jun 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-24755409
5.
Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors.
Biol Blood Marrow Transplant
; 21(8): 1437-44, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25865648
6.
Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis.
Leukemia
; 37(12): 2426-2435, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37848633
7.
Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20-year cohort.
Br J Haematol
; 158(2): 174-185, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22640008
8.
Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial.
Leukemia
; 36(10): 2443-2452, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35999259
9.
Response to tyrosine kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant
; 16(5): 639-46, 2010 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20005967
10.
Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy.
Blood
; 112(12): 4639-45, 2008 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18723428
11.
Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors.
Cell Stem Cell
; 27(1): 110-124.e9, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32413332
12.
IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation.
Biol Blood Marrow Transplant
; 15(2): 205-13, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19167680
13.
Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia".
Sci Transl Med
; 11(501)2019 07 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-31316004
14.
Serotonin syndrome after concomitant treatment with linezolid and meperidine.
Clin Infect Dis
; 46(2): 264-5, 2008 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18171260
15.
Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders.
Cancer Genet Cytogenet
; 181(1): 46-51, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18262053
16.
Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era.
Leuk Res
; 73: 67-75, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30227318
17.
PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia.
Sci Transl Med
; 10(427)2018 02 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29437150
18.
Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
Clin Lymphoma Myeloma Leuk
; 18(11): e481-e491, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30100330
19.
High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: a comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation.
J Clin Oncol
; 23(31): 7994-8002, 2005 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16204014
20.
Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.
Cancer Genet Cytogenet
; 170(1): 16-23, 2006 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16965950